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Abstract
Familial hypocholesterolemia, namely abetalipoproteinemia, hypobetalipoproteinemia and chylomicron retention
disease (CRD), are rare genetic diseases that cause malnutrition, failure to thrive, growth failure and vitamin E
deficiency, as well as other complications. Recently, the gene implicated in CRD was identified. The diagnosis is
often delayed because symptoms are nonspecific. Treatment and follow-up remain poorly defined.
The aim of this paper is to provide guidelines for the diagnosis, treatment and follow-up of children with CRD
based on a literature overview and two pediatric centers ‘experience.
The diagnosis is based on a history of chronic diarrhea with fat malabsorption and abnormal lipid profile. Upper endo-
scopy and histology reveal fat-laden enterocytes whereas vitamin E deficiency is invariably present. Creatine kinase (CK)
is usually elevated and hepatic steatosis is common. Genotyping identifies the Sar1b gene mutation.
Treatment should be aimed at preventing potential complications. Vomiting, diarrhea and abdominal distension
improve on a low-long chain fat diet. Failure to thrive is one of the most common initial clinical findings.
Neurological and ophthalmologic complications in CRD are less severe than in other types of familial
hypocholesterolemia. However, the vitamin E deficiency status plays a pivotal role in preventing neurological
complications. Essential fatty acid (EFA) deficiency is especially severe early in life. Recently, increased CK levels and
cardiomyopathy have been described in addition to muscular manifestations. Poor mineralization and delayed
bone maturation do occur. A moderate degree of macrovesicular steatosis is common, but no cases of
steatohepatitis cirrhosis.
Besides a low-long chain fat diet made up uniquely of polyunsaturated fatty acids, treatment includes fat-soluble
vitamin supplements and large amounts of vitamin E. Despite fat malabsorption and the absence of postprandial
chylomicrons, the oral route can prevent neurological complications even though serum levels of vitamin E remain
chronically low. Dietary counseling is needed not only to monitor fat intake and improve symptoms, but also to
maintain sufficient caloric and EFA intake.
Despite a better understanding of the pathogenesis of CRD, the diagnosis and management of the disease remain
a challenge for clinicians. The clinical guidelines proposed will helpfully lead to an earlier diagnosis and the
prevention of complications.
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Chylomicrons, the principal carriers of dietary lipids, are
triglyceride (TG)-rich lipoproteins secreted exclusively
from the enterocyte. These large lipoproteins (700 to
6000 Å) contain a single molecule of apolipoprotein
(apo) B-48, which is essential for chylomicron structure
cohesion [1,2]. Apo B-100 is found within very-low-den-
sity lipoproteins (VLDL) secreted by the liver and in low-
density lipoprotein (LDL), a catabolic product of VLDL.
Many genetic diseases are responsible for alterations
in apo B synthesis, metabolism or secretion abnormal-
ities, causing intestinal fat malabsorption with growth
retardation and neuro-ophtalmological complications.
Over the last 20 years, genetic abnormalities have been
identified for three main disorders classified as familial
hypocholesterolemia: hypobetalipoproteinemia (HBL),
abetalipoproteinemia (ABL) and chylomicron retention
disease (CRD). Figure 1 illustrates the characteristic lipid
screening profiles and oral responses to a fat load test in
patients and their parents with these disorders.
HBL is due to a mutation in the apo B gene on chro-
mosome 2 leading to a shorter apo B molecule (truncated
apo B) [3]. The clinical phenotype of this autosomal
dominant hypocholesterolemia (Figure 1) is variable, as
homozygous patients are indistinguishable from ABL,
while heterozygotes show only a very mild phenotype [4].
The genetic abnormality leading to ABL was identified
in 1992 [5] and is due to the mutation of the microso-
mal triglyceride transfer protein gene on chromosome 4
[5-7]. This mutation leads to premature degradation of
nascent apo B and then to a drastic decrease in apo
B-containing lipoproteins.
Figure 1 Etiology of familial hypocholesterolemia in childhood depending on lipid profile. ABL, abetalipoproteinemia; AD, autosomal
dominant; AR, autosomal recessive; apo AI, apolipoprotein A1; apo B; apolipoprotein B; HDL, high-density lipoprotein; HBL,
hypobetalipoproteinemia; LCAT, lecithin cholesterol acyltransferase; LDL, low-density lipoprotein; MTP, microsomal triglyceride transfer protein;
N, normal; 0, nul; PL, phospholipids; TC, total cholesterol; CRD, chylomicron retention disease; TG, triglyceride; ↓, few decrease; ↓↓, significant
decrease; ↓↓↓, intense decrease.
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Page 2 of 13Recently, the SAR1B gene was identified as responsible
for CRD or Anderson’s disease (MIM #607689) [8]. The
SAR1B gene encodes the Sar1b protein, which is
involved in chylomicron transport from the endoplasmic
reticulum (ER) to the Golgi apparatus [9,10]. In fact,
Sar1-GTP forms a coating protein complex (COPII)
with two heterodimers Sec23/24 and Sec 13/31, which
initiates budding and captures cargo to eject vesicles
from the ER to the Golgi apparatus. When Sar1b is
muted, the pre-chylomicron transport vesicle delivered
by the ER cannot fuse with the Golgi apparatus, which
then induces an accumulation of pre-chylomicron trans-
port vesicles in the cytoplasm of the enterocytes [11-14].
Genotyping has revealed that Anderson’sa n dC R Da r e
in fact the same disease [8]. Recently, we described
three new mutations in addition to the eight original
genetic defects and a few others have been reported
[8,11,15,16]. These studies have greatly contributed to a
better understanding of CRD for the clinicians who
often experience difficulties with the diagnosis and man-
agement of CRD patients. First, the diagnosis is often
delayed because symptoms are nonspecific (diarrhea,
abdominal distension, vomiting, and failure to thrive)
and hypocholesterolemia may be attributed to malnutri-
tion secondary to chronic diarrhea. Secondly, follow-up
and treatment are poorly defined for many reasons. The
similarity with other types of familial hypocholesterole-
mias may lead to a wrong diagnosis unless molecular
testing is performed. Furthermore, CRD is rare: only
~ 40 cases and two small cohorts with seven and eight
patients each have been described [17-29]. Very long-
term follow-up into adulthood is poorly documented.
However, a few authors report some adult cases with
serious neurological impairment, albeit less severe than
in patients with homozygous ABL or HBL [20,21,27-29].
Finally, to our knowledge, there are no specific recom-
mendations for CRD follow-up or treatment. For the
most part, therapeutic suggestions have been elaborated
based on recommendations for ABL or symptomatic
HBL patients. As the pathogenesis of these diseases dif-
fers, their manifestations and complications lead to
poorer outcomes.
The aim of this paper is to provide an overview of the
disease, comment on recent findings obtained from a
cohort of 16 patients in whom a molecular diagnosis
was made and for whom a median follow-up of five and
ten years was available for the Montreal and Lyon
cohorts, and make recommendations for the diagnosis
and treatment respectively [30].
CRD Diagnosis
CRD diagnosis can be confused with other genetic
hypocholesterolemias characterized by decreased LDL-
cholesterol (LDL-C), such as ABL or homozygous HBL,
or with acquired disorders associated with low high-
density lipoprotein-cholesterol (HDL)-C. Figure 1 sum-
marizes the differences in familial hypocholesterolemia
with low LDL-C. The major clinical and biological man-
ifestations as well as complications are summarized in
Table 1 and steps to diagnose CRD are presented in
Table 2.
Clinical Signs
In CRD, consanguinity is frequent but there is usually
no noted intrauterine growth retardation. Digestive
symptoms are most prominent at the beginning of life.
Nonspecific malabsorptive diarrhea is constant and
begins in infants shortly after birth. Other digestive
symptoms, such as vomiting or abdominal swelling, are
often present. They get better within a few days or
weeks with a low-fat diet. The long-term evolution of
digestive symptoms is variable. The intensity of symp-
toms decreased over time independent of the level of fat
in the diet in some previously reported patients [22].
However, our data do not support the hypothesis of
intestinal adaptation during CRD. Even though our
patients’ gastrointestinal symptoms improved on a low-
fat diet, diarrhea began again when fat was reintroduced,
even in adult patients. Furthermore, there was no
improvement in steatorrhea after an average of five
years of follow-up [30].
Hepatomegaly is reported to occur in about 20% of
CRD patients. Hepatic steatosis is a well known compli-
cation of HBL. However, in CRD, at ultrasonography
hepatomegaly and steatosis were detected in a few cases.
A moderate degree of macrovesicular steatosis was pre-
viously reported [22,27], but, to our knowledge, no case
of cirrhosis has been reported in CRD, in contrast to
ABL and HBL [31-33]. Interestingly, during follow-up,
we did not find any correlation between the level of
hepatic enzymes and steatosis or hepatomegaly. Serolo-
gical testing alone is therefore insufficient to detect
hepatic morphological problems.
Neurological, muscular or ophthalmic manifestations
may raise an alarm in those older patients with a
delayed diagnosis as poor compliance to treatment.
The neurological abnormalities described in CRD
children are: areflexia at ten and 13 years in a French
publication and 13 and 18 years in Strich’s publication;
areflexia combined with proprioceptive abnormalities
at ten and seven years in a Canadian study [21,27,29].
Furthermore, more severe neurological degeneration,
such as ataxia, myopathy and sensory neuropathy, has
been reported in CRD adults 21 and 55 years old
[20,28]. The mean age in the literature of children
with clinical neurological manifestations is 12 years,
which is significantly older than that for asymptomatic
patients (four years). In our cohort, 4/16 patients had
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Page 3 of 13Table 1 Clinical and Biological Expressions of Chylomicron Retention Disease in Studies with Genotyping
Clinical signs Age at onset of
symptoms
Transient or permanent
symptoms
Prevalence in
childhood
Power of
discrimination
Anthropometry
Failure to thrive Infancy (1 to 6 m) transient if low LCFA diet 80% +
Gastrointestinal symptoms and signs
Diarrhea Infancy (1 to 6 m) transient if low LCFA diet 100% +
Vomiting Infancy (1 to 6 m) transient if low LCFA diet 60% +
Abdominal distension Infancy (1 to 6 m) transient if low LCFA diet 65% +
Hepatomegaly, Steatosis Infancy or late childhood transit or permanent 15%
Neurology
Retinopathy Adult permanent 100% +++
Visual abnormalities Late childhood or adult (6
to 10 y)
transient if early treatment 30% +
Hypo or Areflexia Late childhood or adult (4
to 10 y)
permanent 5% +
Myopathy Adult permanent 0% +
EMG abnormalities Late childhood or adult (4
to 10 y)
transient if early treatment 25% +
Decreased proprioception Late childhood or adult (4
to 10 y)
transient if early treatment 0% +
Cardiomyopathy/Biological signs Adult permanent? 0% +
Normal TG
§ Infancy (1 to 6 m) transit or permanent 90% +++
Low Total cholesterol
§§ Infancy (1 to 6 m) permanent 100% moderate decrease
++
Low LDL
† Infancy (1 to 6 m) permanent 100% moderate decrease
++
Low HDL
†† Infancy (1 to 6 m) permanent 100% +++
Normal Fasting lipids in parents 100% +
High CK (N < 100 mmol/L) Infancy (1 to 6 m) - (460 ±
100)
permanent 60% +++
Hepatic cytolysis (ALT < 40 mmol/L) Infancy to late childhood -
(60 ± 20)
transient or permanent 95% +
Vitamin E deficiency (N > 18.4 μmol/L) Infancy (1 to 6 m) - (2.7 ±
0.3)
permanent 95% +
Vitamin A deficiency (N > 1.61 μmol/L) Infancy (1 to 6 m) - (0.8 ±
0.5)
transit if supplementation 70% +
Vitamin D deficiency (N > 50 nmol/L) Infancy (1 to 6 m) - (31 ±
17)
transit if supplementation 45% +
Vitamin K deficiency (N > 2.26 mmol/L) Infancy (1 to 6 m) - (1.15 ±
0.6)
transit if supplementation 45% +
Steatorrhea (N < 5 g/d) Infancy (1 to 6 m) - (7.5 ±
3.6)
transit or permanent 85% +
Negative Oral Fat Load Infancy (1 to 6 m) Permanent ? 100% +
No acantocytosis Infancy (1 to 6 m) transit or permanent 90% +++
EFA deficiency* (20:3n-9/20:4n-6) Infancy to late childhood permanent but variations 55% +
Endoscopic and histological signs
White duodenal mucosa Infancy (1 to 6 m) permanent? Fat load
dependent
100% ++
Enterocyte vacuolization, chylomicron-like Infancy (1 to 6 m) permanent? Fat load
dependent
100% ++
+: no; ++: few; +++: highly discriminative; N: normal.
§ X value (mmol/L) is the same in CRD as in controls (0.73).
§§ X value (mmol/L) is decreased by 60% in CRD (1.49 ± 0.56) vs controls (3.73 ± 0.80).
† X value (mmol/L) is decreased by 75% in CRD (0.69 ± 0.38) vs controls (2.33 ± 0.64).
†† X value (mmol/L) is decreased by 5% in CRD (0.46 ± 0.08) vs controls (1.07 ± 0.22).
*X ratio in CRD is 0.04 ± 0.02 and 0.01 ± 0.005 in controls.
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Page 4 of 13electromyographic abnormalities (electromyography
with a reduction in sensory nerve conduction velocity
and decreased sensory nerve action potential ampli-
tudes). The youngest was 6.5 years old and only one
had areflexia as early as age 11. Vitamin E status plays
a pivotal role in neurological degenerative complica-
tions [34,35]. In our study, it is relevant to note that
the patients with the more pronounced abnormalities
had also the lowest vitamin E levels at diagnosis.
Muscular pain and cramps are rare, but classical com-
plaints have been reported by patients. Recently, cardio-
myopathy with a decrease in ejection fraction to 40%
(normal > 60%) has been described in adults with CRD
[15], but its prevalence is unknown. In our cohort, all
patients had normal echocardiography, and no signs of
cardiomyopathy were found before 23.5 years of age.
Muscle histology did not reveal significant lipid accumu-
lation or necrosis, but rather only mild and nonspecific
abnormalities: a mild increase in lipid content, focal dis-
organization of the Z line with the loss of a few Z lines
in specific regions of the muscle specimen (personal
data), and a variation in muscle fiber diameter with
numerous lobulated fibers [15].
With regard to ophthalmic complications, minimal
visual abnormalities were previously been reported:
micronystagmus, mild deficit in the perception of the
blue-yellow axis, and delayed dark adaptation [27]. In
our populations, ophthalmic complications were mild,
evidenced only through functional testing (abnormal
visual evoked potentials characterized by waves of
higher amplitude and increased latencies, as well as
abnormal scotopic electroretinograms). In conclusion, in
children, the absence of severe neurologic impairment
and retinopathy is compatible with a diagnosis of CRD.
Poor mineralization and delayed bone maturation have
previously been observed in CRD [21], probably as a
consequence of malabsorption, malnutrition and vitamin
D deficiency.
Interestingly, Sar1b GTPase is expressed not only in
the intestine but also in the liver, muscle and brain. The
Table 2 Chylomicron Retention Disease Diagnosis
Clinical
Anthropometry Constant but unspecific failure to thrive in early infancy (1-6 months)
Digestive Chronic malabsorptive diarrhea in early infancy, frequent vomiting and abdominal distension in early infancy
Neurology Areflexia, ↓ deep proprioception, and ataxia are uncommon during childhood and there is no retinopathy
Biological (Fasting State)
Lipids In patients with a suggestive profile:
↓ HDL and N
al TG are the most discriminative specificities of CRD.
↓↓ Total cholesterol and ↓↓ LDL: intensity of decrease only around 50% normal values
Neuromuscular ↑ (1.5-4N) CK discriminative but inconstant abnormalities for CRD
Blood Cell Count Absence of acanthocytosis in infancy is more frequent in CRD than in AB or HB
Hepatic Frequent and early but not specific ↑ (1.5-3N) AST and/or ALT, with normal GGT, bilirubin and alkaline phosphatase
Liposoluble vitamins Unspecific decrease ↓↓↓ E is the most severe and only permanent vitamin deficiency even with supplementation, ↓↓ A, ↓ -
N
al D, ↓ -N
al K
Coagulation ↓ -N
al INR. Decreased INR if there is vitamin K deficiency
Plasma fatty acid Abnormal profile, omega 6 linoleic acid deficiency, normal omega 3
Fasting lipids in
parents
N
al
Oral Fat Load
TGs are normal at baseline but do not increase postprandially and lack of change in low HDL after fat load
Upper Endoscopy (fasting state or after enriched fat diet for 3 days)
Unspecific white duodenal mucosa
Optic microscopy Villi are normal but the enterocytes are grossly distended by lipid droplets
Electron microscopy Chylomicron-like aggregates, membrane bound?
Genotyping
Mutations in SAR1B, Chromosome 5
Summary
1) Chronic diarrhea in young infants (< 6 Mo). Normal TG with decreased total cholesterol, LDL-C and HDL-C
2) Failure to thrive
3) White duodenal mucosa at endoscopy® genetic hypocholesterolemia?
4) Genetic mutation of SAR1B ® CRD confirmed
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyltranspeptidase; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-
density lipoprotein-cholesterol; TG, triglycerides; INR, international normalized ratio; N
al, Normal.
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fic failures, for example, hepatocyte transport of nascent
V L D Lf r o mt h eR Et ot h eG o l g it h a n k st oaS a r 1 b -
dependant mechanism [36]. We can hypothesize that
this dysregulation may be involved in the hepatic steato-
sis described in CRD. Furthermore, the myocardium has
been shown to express the Sar1b gene and secrete apo
B lipoproteins [37,38]. This suggests that the recent
description of cardiomyopathy in CRD may be related
to the tissue-specific expression of abnormal Sar1b pro-
tein. Finally, mild musculoskeletal and neurological
abnormalities could also be related to impaired Sar1b in
various systems [7,11].
Biological Signs
Hypocholesterolemia associated with chronic diarrhea is
common and nonspecific. However, CRD may be sus-
pected with a particular lipid profile. First, the more than
50% decrease in total cholesterol (1.49 ± 0.56 in CRD vs
3.73 ± 0.80 mmol/L in control patients), LDL-C (0.69 ±
0.38 in CRD vs 2.33 ± 0.64 mmol/L in control patients)
and HDL-C (0.46 ± 0.08 in CRD vs 1.07 ± 0.22 mmol/L in
control patients) in the presence of normal triglycerides
(TG) (0.73 mmol/L) is almost pathognomonic [30,39]. In
contrast, both AB and homozygous HB have hardly any
measurable TGs much lower total cholesterol levels and
no LDL-C. Interestingly, in CRD, the intense hypocholes-
terolemia is not associated with consequences as severe as
in the AB or HB homozygotes. First, the dyslipidemia is
much less severe than in AB and HB. Secondly, in CRD,
the chylomicrons are not secreted in the classic COP II
way, but are built into the RE. Intestinal biopsies show
chylomicron-like particles in membrane-bound compart-
ments, reminiscent of the vesiculated channels of the
smooth ER and in big membrane-bound compartments
[19]. We can, therefore, presume that some fat is trans-
ported via LDL particles throughout the day and hardly
detectable during the 5-hour fat loading test. However, at
the puncture, no data support this possibility.
CRD and AB are recessive autosomal diseases, unlike
HB which is a dominant form of hypocholesterolemia.
Therefore, parental lipid screening may clarify the diag-
nosis. The absence of hypocholesterolemia in the two
parents favors CRD.
Interestingly, the measurement of creatine kinase (CK)
may orient towards the diagnosis. Recently and for the
first time, muscular abnormalities have been described in
CRD patients [15]. In our cohort, CK levels were elevated
(5 × N) in all patients in whom the measurement was
made at diagnosis, except one. The highest level (10 × N)
was found in a patient who had the most severe level of
neurological impairment (areflexia and abnormal electro-
myography). However, the CK level does not always corre-
late well with the severity of the neurological impairment.
In conclusion, an elevated level of CK in a patient with
hypocholesterolemia can suggest CRD.
Acanthocytes can be seen in advanced liver disease,
rare vitamin E genetic deficiency or neurodegenerative
syndromes (McLeod), AB, or homozygous HB. In CRD,
acanthocytosis is rare, and sometimes transient. It is
dependent on the vitamin E level which is a key to red
cell membrane integrity. Therefore, the presence of
acanthocytosis is hardly compatible with CRD.
As previously mentioned, hepatic abnormalities may
be present. Nonspecific hepatic cytolysis is very fre-
quent, but moderate, (1.5-3 × N), and poorly correlates
with steatosis and/or hepatomegaly.
Malabsorption of fat leads to deficiency of fat soluble
vitamins and essential fatty acid (EFA). Steatorrhea at
the time of diagnosis (usually a few months after the
onset of the first symptoms) is invariably present and
depends on the quantity of fat ingested. With a low-fat
regimen, steatorrhea may be falsely negative. The calcu-
lation of % fat absorption on a normal fat diet is a key
diagnostic test in all patients suspected of CRD.
Fat malabsorption alters fat-soluble vitamins in vari-
able ways. Vitamin E is the most affected among the
liposoluble vitamins in CRD, because its transport is
highly dependent on apo B-containing lipoproteins [40].
Vitamin E deficiency is constant at diagnosis in young
children. In CRD, the decrease is drastic and most of
t h et i m ep e r m a n e n t ,e v e nw i t h vitamin E supplementa-
tion. Vitamin A is often decreased, but easily corrected
with oral supplementation. Finally, vitamin D or K
insufficiency detected in half the patients can also be
corrected with supplements.
Fat malabsorption also affects the EFA profile. At
diagnosis, our CRD patients had abnormal plasma fatty
acid profiles, as evidenced by n-6 deficiency (linoleic
acid; C18:2n-6) and, surprisingly, normal omega-3 levels.
In addition, EFA deficiency manifested by a high 20:3n-
9/20:4n-6 ratio, (0.04 ± 0.02 in CRD vs 0.01 ± 0.005 in
control patients); normal value <0.02 was observed in
the Canadian cohort [30].
The oral fat loading test helps evaluate intestinal fat
absorption. Patients fast for 12 h and ingest 50 g of fat
per 1.73 m
2 surface area (flavored commercial cream).
Plasma lipids are measured at 2, 3 and 5 h following the
fat meal. All patients with CRD do not respond to an oral
fat loading test: TGs are normal or slightly decreased at
baseline and do not increase at 3 and 5 h while low
HDL-C stays low and no chylomicrons are identified.
However, this test does not discriminate CRD from the
other genetic disorders with hypocholesterolemia.
Endoscopy and Histology
Upper endoscopy reveals a white duodenal mucosa with
normal esophageal and normal gastric mucosa (Figure 2).
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Page 6 of 13Figure 2 Endoscopy of a CRD patient. Upper endoscopy reveals a white duodenal mucosa in CRD (Panel A) compared with normal subjects
(Panel B).
Figure 3 Histology of a jejunal biopsy from a CRD patient. Panel A: photomicrograph of hematoxylin-eosin staining showing vacuolization of
enterocytes and well preserved villous structure. The distribution of vacuolization, which corresponds to lipid droplets, is heterogeneous: fat filled
enterocytes (black arrow) in the upper part of the villus are associated with normal enterocytes in the crypts (white arrow) (×20). Panel B: Higher
magnification (×100) of the same patient’s biopsy. Panel C: Electronic microscopy. The pictures show the apical pole of the enterocytes exhibiting
well-preserved microvilli (black arrow), numerous chylomicrons (CM) and fat droplets of homogenous size gorging the cytoplasm (Cy). The
intercellular membranes demonstrate a complete juxtaposition of intercellular membranes where lipid particles are absent (white arrow) (×4000).
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begun three days before the exam to improve the fat
loading of enterocytes.
Histology shows multi-vacuolated enterocytes in
intestinal villi of normal architecture (Figure 3). How-
ever, some patients demonstrate mild atrophic villi [21],
which may be confused with celiac disease if lipid
vacuoles are not identified. Furthermore, in the same
patient, villi are affected to a variable extent and, among
different patients, the percent of lipid-laden villi and the
region of affected villi can vary substantially [19]. In
most cases, the vacuolization is seen only in the upper
one-third of the villi.
Genetics
Finally, identification of the SAR1B gene mutation
confirms the diagnosis. Since the discovery of SAR1B
as the gene that causes CRD [8], 14 different mutations
in about 30 patients have been described (Figure 4)
[8,11,16,41]. Only two families have had frame shift
mutations that cause CRD. Until now, missense
mutations have represented the majority of SAR1B
mutations. We previously reported the absence of a cor-
relation in genotype-phenotype in a cohort of 16
patients with CRD [30] and Charcosset et al. analyzed
the putative consequences of different mutations includ-
ing frame shift and missense mutations in CRD. Trun-
cating variants would be expected to induce more
severe phenotypes than just missense variants. However,
the most deleterious mutation of lipid levels or growth
reported in our cohort was a missense mutation
(409G > A) [30]. Furthermore, the variation in clinical
expression with the same mutation in different families
[11] and even in the same family with the very surpris-
ing asymptomatic homozygote CRD mother, described
by Cefalu et al [41], suggests that modifier genes may
modulate the transport of the COP II vesicles and that
CRD expression is more complex than a simple autoso-
mal recessive disorder.
CRD Management
Follow-up should be directed toward monitoring nutri-
tion and growth, compliance to treatment and the
presence of complications involving the liver, the neuro-
muscular system including the retina as well as bone
health. Table 3 proposes a long term management pro-
gram proposed for patients with CRD.
Growth is a pediatric-specific goal in patients with
malabsorption syndromes. With early diagnosis and
treatment, catch-up growth can be expected. However,
Figure 4 Mutations of SAR1B gene as described in the literature. Encoding exons are in grey colour. The nomenclature used is the same as
that reported by Jones et al. [8] Sequences of SAR1B gene (NC_000005, gi: 51511721) and mRNA (NM_016103, gi: 38176155) are available on
GenBanck (http://www.ncbi.nlm.nih.gov). Only predicted consequences of mutations are presented; mutations from 5’ to 3’ are: c.1-4482_58 +
1406del5946ins15pb, c.32G > A, c.83-84 delTG, c.109G > A, c.224A > G, c.349-1G > C, c.364G > T, c.409G > A, c.499G > T, c.536G > T, c.537T > A,
c.542T > C, c.554G > T, c.555-558dupTTAC.
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even reach the 20
th percentile of their predicted growth
potential of the 40
th percentile. Tracking the growth
curve is essential in the follow-up of CRD children.
Annual evaluation is appropriate.
The evolution of hepatic cytolysis seems favorable. How-
ever, the lack of very long-term data means that patients
should be followed carefully. Therefore, measurement of
hepatic transaminase levels and ultrasonography should
both be carried out. An evaluation every three years after
the age of ten seems a reasonable frequency for these non-
invasive low-cost exams. Liver stiffness measured by elas-
tometry (Fibroscan) could be a useful tool to detect early
fibrosis, but this proposal needs further evaluation.
Neurological, muscular and ophthalmologic complica-
tions in CRD are less severe than in ABL or homozygous
HBL, but may occur during infancy and require rigorous
follow-up and compliance with vitamin treatments. The
lack of data on long-term outcome in treated patients with
CRD means that rigorous follow-up is required. Although
high CK levels may indicate severe muscular impairment,
they are inadequate to evaluate neuromuscular progres-
sion. Therefore, beginning at pre-puberty (ten years old),
neurological and ophthalmologic examinations may be
necessary every three years to detect complications such
as developmental retardation, areflexia, ataxia, dysarthria,
loss of deep proprioception, muscular weakness and
decreased night vision. Furthermore, it seems reasonable
to schedule a specialized neurology and ophthalmology
consultation every three years to conduct electromyogra-
phy, measure visual evoked potentials, and perform elec-
troretinography, because electrical abnormalities occur
before clinical symptoms. Finally, we suggest echocardio-
graphy in adulthood (>18 years), since early detection of
cardiac impairment may motivate patients who have dis-
continued their vitamin therapy to restart it. It may also
help to schedule treatment before clinical manifestations
of cardiac insufficiency develop. A frequency of every
three years seems reasonable for this noninvasive exam.
Dual-energy X-ray absorptiometry (DEXA) may be
performed to measure the bone mineral content of the
total skeleton, the best index of bone mineralization in
children [42,43].
CRD Treatment
Table 4 summarizes our proposed treatment protocol.
A low-fat diet containing an appropriate amount and
ratio of n-6/n-3 is necessary to improve digestive symp-
toms. In very young children, milk preparations with
medium-chain TG may improve diarrhea and correct
malnutrition within a few days but tolerance can be a
problem. In older children, a regimen low in long-chain
fatty acids is usually sufficient to decrease symptoms.
Vitamins E and A are implicated in neurological,
muscular and ophthalmic complications. High dosages
of vitamin E (100 IU/kg/d) have been reported to
Table 3 Chylomicron Retention Disease Follow-Up
Early Follow-Up (Annual)
Clinical
Anthropometry Weight and height to draw growth curve
Digestive Appetite, diarrhea, abdominal distension, vomiting, hepatic size?
Neurological Developmental retardation, areflexia, ataxia, dysarthria, deep proprioception loss, muscular weakness or pain,
cramps?
Dietary counseling Sufficient caloric intake, low fat diet (fat <30% total energy), EFA supplementation?
Biological
Lipids Total and LDL cholesterol, HDL-C, TG
Hepatic AST, ALT, GGT, total bilirubin, alkaline phosphatase?
Vitamins Plasma levels of vitamins A, D, E and K or INR (vit K deficiency)
Essential Fatty Acids Deficiency induced by low fat diet?
Blood cell count Anemia?
Delayed Follow-Up (every 3
years)
1) After the age of 10 years
Hepatic Ultranosonography (steatosis, portal hypertension, yearly), Elastometry Fibroscan®? (further studies are needed)
Neurological exam Clinical, creatine kinase, electromyography
Ophthalmologic exam Fundus, color vision, visual evoked potentials, electroretinography
Total body composition Bone mineral content for whole body
2) Adult age
Echocardiography Ejection fraction
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase; EFA, essential fatty acids; GGT, gamma-glutamyltranspeptidase; HDL, high-
density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides.
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different hypocholesterolemia disorders such as ABL
[35,44-48]. Furthermore, these high intakes are safe.
Relatively few side effects in the short term have been
reported in double-blind studies of vitamin E at doses
as high as 2000 or 3200 IU/d [49]. Alpha-tocopherol
either in aqueous or lipid form is the most effective
form of vitamin E to prevent neurological complica-
tions. Indeed, nerve tissue is characterized by slow
exchange and high selectivity for alpha-tocopherol
[50]. Lipid malabsorption is a common feature of sev-
eral diseases, such as celiac disease, cystic fibrosis and
cholestasis. In the attempt to promote liposoluble vita-
min absorption, new pharmacologic formulations of
vitamin E have been developed. Tocopheryl polyethy-
lene glycol succinate is a hydrosoluble form of vitamin
E. This water-soluble formulation showed a marked
and statistically significant increase in the absorption
of gamma-tocopherol in malabsorbing patients with
cystic fibrosis (CF) compared with a classic oil-based
formulation [51]. Recently, intestinal absorption of
water-soluble vitamin E (tocofersolan) was compared
with a water-miscible form in 12 CF or cholestatic
children [52]. Oral tocofersolan was more bio available
t h a nt h ew a t e r - s o l u b l ef o r m u l a t i o ni nc h i l d r e nw i t h
chronic cholestasis and similarly bio available in CF.
This suggests that water-soluble vitamin E may repre-
sent an alternative to painful intramuscular vitamin E
injections in chronic cholestasis, or other oral formula-
tions in CF. However, the mechanism responsible for
fat malabsorption in CRD concerns the absorptive
phase as opposed to the digestive phase in CF and
cholestatic syndromes. To our knowledge, no specific
studies with these new vitamin E preparations have
been conducted in CRD. For CRD, further investiga-
tion on the efficacy of water-soluble vitamin E is
needed. Our 16 CRD patients received an average of
51 ± 32 IU/kg/d of vitamin E with some receiving a
dosage as high as 100 IU/kg/d. Despite higher dosages
of oral vitamins E and A and, in some cases, compli-
ance ensured by intravenous administration, four of
the seven French patients developed mild clinical signs
of neurological impairment. This may be due to the
delayed diagnosis or influence of the mutation. How-
ever, the majority of patients (12/16 patients) with a
medium dosage of 50 IU/kg/d, sometimes as low as 20
IU/kg/d, did not develop clinical or electrical neuro-
ophthalmologic complications when the treatment was
given during the first years of life. Therefore, it seems
reasonable to prescribe only 50 IU/kg/d of vitamin E
to patients with CRD if the disease is diagnosed during
the first year of life.
To prevent complications, our data do not suggest
that the intravenous route is warranted. The oral route
is sufficient, as illustrated by the nine patients in the
Canadian cohort who were treated orally early on and
who remained free of neurological complications
(including two patients aged 22).
Determination of the appropriate dosage of vitamin E
can be problematic. In our cohort, plasma concentration
measurements were too imprecise to serve as a guide
for clinicians. Plasma levels after supplementation
reached only one half to two thirds of normal levels,
independent of the vitamin E dose. Among the 16
patients with 20, 40 or 100 IU/kg/d, one may find the
same plasma vitamin E levels of around 60% of the
lower normal range. This level is comparable with that
obtained in ABL after oral supplementation with high
doses (45% of the normal range for 100 IU/kg/d of vita-
min E) [53]. Furthermore, plasma levels of vitamin E did
not necessarily correlate with vitamin E dosages. The
severity of steatorrhea was not correlated with vitamin E
Table 4 Chylomicron Retention Disease Treatment
Early diagnosis without neurological complications: PO Delayed diagnosis and neurological complications: PO + IV
Diet
Low-fat diet
Enriched in essential fatty acids (vegetable oils, fish...)
± Enriched in medium-chain triglycerides
Liposoluble Vitamins PO
Vitamin E (hydrosoluble form): 50 IU/kg/d
Vitamin A: 15,000 IU/d (adjust according to plasma levels)
Vitamin D: 800-1200 IU/kg/d or 100,000 IU/2 month if < 5 y old, and 600,000 IU/2 month if > 5 y old
Vitamin K: 15 mg/week (adjust according to INR and plasma levels)
One perfusion/month
Fatty acids: intralipid 20% 2 g/kg/month
Vitamin E: 4 to 6 mg/kg/month
Vitamin A: 500 IU/kg/month
PO, per os; IV, intravenous.
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treatment cannot be adjusted to the severity of fat
malabsorption. An interesting alternative could be to
measure vitamin E levels in subcutaneous adipose tissue.
It was previously demonstrated that after supplementa-
tion, adipose tissue concentrations reach normal levels,
even if plasma levels remain low [54].
Experience with our 16 patients suggests that vitamin
A at a dosage of 15000 IU/d is effective in combination
with vitamin E to prevent ophthalmologic complications
in CRD.
When vitamin D treatment (800 to 1200 IU/d) is
started early, it prevents osteopenia, as illustrated by the
nine Canadian patients.
Vitamin K was administered at the same dosage of
15 mg/week in the two groups. The plasma values were
not measured, but coagulation screening was normal
and no hemorrhages were detected in any patient during
the entire follow-up.
Patients with lipid malabsorption are at an increased
risk for EFA deficiency. Such as mentioned previously, a
low-fat diet is necessary to improve digestive symptoms,
but it may increase the risk of EFA deficiency. There-
fore, dietary counseling is needed not only to decrease
fat intake but also to maintain sufficient caloric and
EFA intake. It was recommended that the nine Cana-
dian patients add one to three teaspoons per day of soy-
bean oil to meals and increase fish consumption to two
to three times per week. The objective was to reach
3-5% of total calories with omega 6, and 0.5-1% with
omega 3. The French cohort (seven patients) had the
same dietary recommendations, but each month four of
them also received an infusion of 80 g of lipid emulsion
containing 8 g of EFA (linoleic, 80% olive oil and 20%
purified soy oil). The other three patients drank 25 g
per day of oral supplements containing medium-chain
TG (Liprocil, 80% MCT, Nestlé, France). Intravenous
and oral supplementations were unable to normalize the
EFA plasma levels. Furthermore, the clinical impact of
this supplementation is not obvious, since the Canadian
cohort had less supplementation and worse plasma
levels, but fewer complications. This discrepancy may be
explained by a difference between plasma fatty acid
levels and the fatty acid concentration in tissues, since
dietary fatty acids are mainly carried by chylomicron
vesicles, which are dramatically decreased in CRD. Adi-
pose tissue biopsies could provide some answers to this
question. Simple counseling to increase oral EFAs with
vegetable oils and fish seems appropriate in CRD, as
illustrated by the excellent clinical progression of the
nine Canadian patients despite the low plasma omega-6
levels. However, prospective clinical studies with fatty
acid supplementation are needed to evaluate the optimal
dose, route of administration and long-term impact of
EFA treatment. Similarly, the role of medium-chain TG
supplementation in CRD patients remains to be defined.
Conclusions
CRD diagnosis and management remain challenging for
clinicians. Significant progress has been made with
regard to the pathogenesis of CRD, the relationship
between genotype and phenotype and its outcome.
Thanks to the experience of two medical centers and a
review of the literature, this paper proposes clinical
guidelines for the diagnosis, follow-up and treatment
of CRD.
The major clinical and biological features of CRD are
summarized in Table 2:
In infants under six months the disease presents as
chronic malabsorptive diarrhea with malnutrition asso-
ciated with an altered lipid profile: TGs are normal but
both LDL-C and HDL-C are below 50% of normal
levels, vitamin E deficiency and elevated CK are asso-
ciated. In older children: there is in variably a history of
chronic diarrhea with stunting of growth and delayed
puberty eventually associated with mild neurological
impairment and elevated CK. Hypocholesterolemia is
also present with the same pattern, but may be over-
looked. Chronic mild cytolysis of liver cells with an
echographic pattern of steatosis may be an indication
for screening. In both situations, endoscopy reveals a
white duodenal mucosa by fat-laden enterocytes.
For follow-up (Table 3): During childhood, standard
clinical examination and biological evaluations should
be performed annually, focusing on nutrition growth,
gastrointestinal, liver and neurological manifestations
and complications.
In children over the age of ten, neurology and
ophthalmology consultations bone densitometry should
be obtained every three years. An echocardiogram can
be added to those when adulthood is reached.
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